RADIOPHARM THERANOSTICS LIMITED (RAD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RAD

RAD - RADIOPHARM THERANOSTICS LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.019

12 Dec
2025

-0.002

OPEN

$0.02

-9.52%

HIGH

$0.02

2,182,463

LOW

$0.02

TARGET
$0.05 163.2% upside
FNARENA'S MARKET CONSENSUS FORECASTS
RAD: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 1.8 - 1.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 2022202320242025
EPS Basic xxxxxxxxx-1.8
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx3.6 M
Book Value Per Share xxxxxxxxx1.9
Net Operating Cash Flow xxxxxxxxx-36.6 M
Net Profit Margin xxxxxxxxx-1,010.15 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2022202320242025
Return on Capital Employed xxxxxxxxx-100.67 %
Return on Invested Capital xxxxxxxxx-100.67 %
Return on Assets xxxxxxxxx-46.31 %
Return on Equity xxxxxxxxx-100.67 %
Return on Total Capital xxxxxxxxx-125.34 %
Free Cash Flow ex dividends xxxxxxxxx-36.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2022202320242025
Short-Term Debt xxxxxxxxx0 M
Long Term Debt xxxxxxxxx0 M
Total Debt xxxxxxxxx0 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx29 M
Price To Book Value xxxxxxxxx1.16

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2022202320242025
Capex xxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxx6 M
Selling, General & Admin. Exp & Other xxxxxxxxx41 M
Research & Development xxxxxxxxx25 M
Investments - Total xxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

15/12/2025

1

Speculative Buy

$0.05

163.16%

Bell Potter emphasies RAD101 (Pivalate) is the only novel PET imaging agent targeting fatty acid synthase (FASN) which is offering clearer differentiation between recurrent tumour and necrosis than MRI. This could potentially enable earlier, more precise treatment decisions.

Interim phase 2b data from the first three of a planned 30 patients showed tumour uptake in all, with two demonstrating unequivocal uptake, and 15 patients had been recruited by 17 November 2025.

Radiopharm Theranostics is well funded following a recent $35m placement and has potential additional funding via listed options, providing an expected cash runway into 2027. The analyst believes the technology is a major improvement for patient care.

The broker retains a Buy (Speculative) rating and 5c target price, noting upcoming interim data this month and highlighting Lantheus’ 14.5% shareholding as a strategic positive for future development.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.30 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

RAD STOCK CHART

FNArena News on RAD

1
Next Week At A Glance – 10-24 Oct 2025

Oct 17 2025 - Weekly Reports
2
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
3
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps
4
Dr Boreham’s Crucible: Radiopharm Theronostics

Apr 13 2023 - Small Caps
5
Australian Broker Call *Extra* Edition – Mar 21, 2023

Mar 21 2023 - Daily Market Reports